Vectus Biosystems Ltd has released a press release.
Third S.A.D. Group Reviewed By Trial Safety Review Committee
Filed with ASX ·
6ix hasn’t read this filing yet.
Vectus Biosystems Limited on 6ix
Earlier from Vectus Biosystems
- Response to ASX Price and Volume Query
- Update on Phase I Human Trial
- Successful Completion of First Group in Phase I Human Trial
- Approval Received for Phase I Trial in Australia
- Vectus completes $7 million placement
Later from Vectus Biosystems
- Chairman & CEO Address to Shareholders
- A Significant Milestone for VB0004
- Half Yearly Report and Appendix 4D
- Completion of Final S.A.D. Study and First M.A.D. Study
- Quarterly Activities Report & Appendix 4C
Follow Vectus Biosystems into a list and get an email when it puts out news.
Follow Vectus Biosystems